Dr. Harrison brings over a decade of global experience in strategy and implementation, corporate and business development and team leadership. Most recently, Dr. Harrison served roles within RA Capital Management and their portfolio company Imbria Pharmaceuticals. At Imbria, Dr. Harrison served as the Head of Rare Diseases and tasked with the strategy development and execution of two preclinical rare disease programs. In addition, Dr. Harrison was the Head of Portfolio Management and Strategic Planning at the Novartis Institutes for Biomedical Research from 2015-2018 during a period of leadership change and portfolio prioritization. She spent five years with Bain & Company, a global strategy consultancy, across Europe, the Americas and Australia, serving primarily pharmaceutical clients on corporate and product strategies and large-scale transformation programs. She received her Bachelor of Biotechnology in Drug Design & Development, and Ph.D in Structural and Protein Biochemistry from The University of Queensland in Australia.